Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib with or without vinorelbine in HER2-overexpressing inflammatory breast cancer
2010-024454-10Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of afatinib in inflammatory breast cancer (IBC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Primary endpoint (afatinib monotherapy) and Primary endpoint (afatinib plus vinorelbine). Started Apr 2011; status: completed.
02
Drugs
afatinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2010-024454-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024454-10.